www.scottishmedicines.org.uk

Healthcare Improvement Scotland | SMC Advice on new medicines

Statement of advice
SMC2621

crizotinib hard capsules (Xalkori®)

Pfizer Limited

04 August 2023

ADVICE: in the absence of a submission from the holder of the marketing authorisation

crizotinib (Xalkori®) is not recommended for use within NHSScotland.

Indication under review: as monotherapy for the treatment of paediatric patients (age ≥6 to <18 years) with:

- relapsed or refractory systemic anaplastic lymphoma kinase (ALK) positive anaplastic large cell lymphoma (ALCL)
- recurrent or refractory anaplastic lymphoma kinase (ALK) positive unresectable inflammatory myofibroblastic tumour (IMT).

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after careful consideration and evaluation of the available evidence. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair
Scottish Medicines Consortium

Published 11 September 2023